On January 19, 2016 MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage immuno-oncology drug development company reported that it has closed on the first part of a financing agreement with a leading life sciences and healthcare lender(Press release, MabVax, JAN 19, 2016, View Source [SID:1234508803]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The financing agreement will provide the Company with up to $10 million in senior secured debt financing. The Company received an initial loan of $5 million, before approximately $381,000 in issuances costs, with an additional $5 million to be released contingent upon achieving certain milestones. The net proceeds of the initial tranche of debt financing will supplement the Company’s cash position, following a $2.75 million public offering which the Company previously announced was completed in October 2015. The proceeds of the debt financing transaction, together with the public offering, will help advance the Company’s lead antibody-based product HuMab-5B1, recently authorized by the U.S. Food and Drug Administration (FDA) to proceed with the first of two Phase 1 clinical trials, in 2016. The funds will also be used to advance other anti-body and diagnostic products in the pipeline in 2016.